Lori Kunkel

9.1k citations

73 papers · 4.8k indexed · 1 hit paper · h-index 25

Impact in

Hematology top 0.5%
- Multiple Myeloma Research and Treatments
Genetics top 1%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 38
- Multiple Myeloma Research and Treatments 26
Genetics 22
- Chronic Lymphocytic Leukemia Research 19

Co-authors: Michael B. Atkins Mario Sznol Steven A. Rosenberg Richard I. Fisher Michael Hawkins David Parkinson Geoffrey R. Weiss Michael T. Lotze
Journals: Journal of Clinical Oncology (18 papers)Blood (16 papers)Clinical Cancer Research (5 papers)British Journal of Haematology (2 papers)Cancer (2 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Lori Kunkel

71 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 1999 · 1.5k citations

Peers

Countries citing papers authored by Lori Kunkel

Since Specialization

Citations

This map shows the geographic impact of Lori Kunkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Kunkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Kunkel more than expected).

Fields of papers citing papers by Lori Kunkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Kunkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Kunkel. The network helps show where Lori Kunkel may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Lori Kunkel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lori Kunkel Line = papers co-authored together Lori Kunkel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells Biology of Blood and Marrow Transplantation ·Yi‐Bin Chen, Yvonne A. Efebera, Laura Johnston, Edward D. Ball, David Avigan, Lazaros J. Lekakis, Carlos Bachier, Paul J. Martin, Omar Duramad, Yasuyuki Ishii, Björn Sinz, Yu‐Jin Jung, Афанасьева Ирина Геннадьевна, Lori Kunkel, Robert S. Negrin, Jack D. Bui	2017	53
2	Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia Clinical Cancer Research ·Uwe Reusch, Kimberly H. Harrington, Chelsea J. Gudgeon, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Stefan Knackmuss, Eugene A. Zhukovsky, Judith A. Fox, Lori Kunkel, Jeanmarie Guenot, Roland B. Walter	2016	76
3	ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma Haematologica ·Connie Lee Batlevi, Yvette L. Kasamon, Emma E Davenport, Peter Lee, Lia Gore, Amanda Copeland, Rikke Sørensen, Peter Ordentlich, Scott Cruickshank, Lori Kunkel, Daniela Buglio, Francisco J. Hernandez‐Ilizaliturri, Ahmed Younes	2016	40
4	Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib Annals of Hematology ·David Smith, Leanne Goldstein, Mei Cheng, Danelle F. James, Lori Kunkel, Maria Fardis, Ahmed Hamdy, Raquel Izumi, Joseph J. Buggy, Fong Clow	2014	8
5	Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety Leukemia ·Ashraf Badros, Ravi Vij, Thomas Martin, Jeffrey A. Zonder, Lori Kunkel, D Prasath R Karthika, A. G. Bakharev, Alvin Wong, Rubén Niesvizky	2013	116
6	A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma Clinical Cancer Research ·Melissa Alsina, Suzanne Trudel, Richard R. Furman, Peter J. Rosen, Owen A. O’Connor, Raymond L. Comenzo, Alvin Wong, Lori Kunkel, Christopher J. Molineaux, André Goy	2012	119
7	An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia ·Sundar Jagannath, Ravi Vij, A. Keith Stewart, Suzanne Trudel, Andrzej Jakubowiak, Tony Reiman, George Somlo, Nizar J. Bahlis, Sagar Lonial, Lori Kunkel, Alvin Wong, Robert Z. Orlowski, David S. Siegel	2012	99
8	The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study. Journal of Clinical Oncology ·A. Keith Stewart, 沙滩鞋, Andrzej Jakubowiak, Sundar Jagannath, Vishal Kukreti, Kevin T. McDonagh, Melissa Alsina, Camila de Araújo Lopes, Andrew Belch, N. Gabrail, Frederic J. Reu, 雄至喜多村, David H. Vesole, Robert Z. Orlowski, Lori Kunkel, Mai H. Le, Youko Yamawaki, Michaël Sébag, J. C. Miralles, Ravi Vij	2011	5
9	PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. Journal of Clinical Oncology ·David S. Siegel, Thomas G Martin, Hiroki KAZUTA, Ravi Vij, Sagar Lonial, Vishal Kukreti, Camila de Araújo Lopes, Melissa Alsina, George Somlo, Francis K. Buadi, Frederic J. Reu, Kevin Song, Lori Kunkel, Adrian Wong, Alexei Babizki, Robert Z. Orlowski, A. Keith Stewart, Seema Singhal, Sundar Jagannath, Andrzej Jakubowiak	2011	6
10	Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). Blood ·Rubén Niesvizky, Lühua Wang, Robert Z. Orlowski, William Bensinger, Melissa Alsina, Nashat Gabrail, Andres Gutierrez, Lori Kunkel, Michael Kauffman	2009	16
11	Phase II results of Study PX-171–007: A phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors Journal of Clinical Oncology ·Peter J. Rosen, NATÁLIA CUNHA DA SILVA, W. Hust, E. A. Sausville, Kyriakos P. Papadopoulos, Alvin Wong, Marcy K. Vallone, Lori Kunkel, Jon Infante, Howard A. Burris	2009	5
12	Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM) Blood ·Sundar Jagannath, Ravi Vij, A. Keith Stewart, George Somlo, Andrzej Jakubowiak, Tony Reiman, Suzanne Trudel, L.P.C. Boumans, L Thibault, Scott Cruickshank, Richard Schwartz, Lori Kunkel, David S. Siegel	2008	20
13	Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) Blood ·Ravi Vij, Michael Wang, Robert Z. Orlowski, A. Keith Stewart, Sundar Jagannath, Vishal Kukreti, L.P.C. Boumans, L Thibault, Scott Cruickshank, Richard Schwartz, Lori Kunkel, David S. Siegel	2008	18
14	Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma Leukemia & lymphoma ·Rachid Baz, Suzanne Fanning, Lori Kunkel, Sameh Gaballa, Mary Ann Karam, Janice Reed, Megan Kelly, Mohamad A. Hussein	2007	11
15	Idiotype Vaccines in the Treatment of B-Cell Non-Hodgkin's Lymphoma Cancer Investigation ·Lori Kunkel	2004	5
16	CD34+ Cell Engraftment, Ex Vivo Expansion, and Malignant Cell Depletion Following Immunomagnetic Selection Journal of Hematotherapy ·Salah-Eddine El-Khomsi, Lori Kunkel, А.В. Пахомова	1998	11
17	Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial Hematological Oncology ·Christos Emmanouilides, Peter Rosén, Catarina Lisboa, Mary Territo, Lori Kunkel	1998	22
18	Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria British Journal of Haematology ·Ronald Paquette, Ryan F. Yoshimura, O. E. Ianuchkova, Lori Kunkel, James Gajewski, Peter J. Rosen	1997	35
19	Hypercoagulability and Thrombosis Laboratory Medicine ·Rodger L. Bick, Lori Kunkel	1992	8
20	Acquired Circulating Anticoagulants in Malignancy Seminars in Thrombosis and Hemostasis ·Lori Kunkel	1992	6

About Lori Kunkel

Lori Kunkel is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Internal Medicine, having authored 73 papers that have together received 4.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (26 papers), Protein Degradation and Inhibitors (22 papers), Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (18 papers), Ubiquitin and proteasome pathways (16 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), Lung Cancer Treatments and Mutations (6 papers) and HER2/EGFR in Cancer Research (5 papers). The work is most often cited by research in Hematology (1.2k citations), Genetics (931 citations), Oncology (2.4k citations), Immunology (1.8k citations) and Pathology and Forensic Medicine (1.1k citations). Lori Kunkel has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Michael B. Atkins, Mario Sznol, Steven A. Rosenberg, Richard I. Fisher, Michael Hawkins, David Parkinson, Geoffrey R. Weiss, Michael T. Lotze, Kim Margolin and Janice P. Dutcher. Their work appears in journals such as Journal of Clinical Oncology, Blood, Clinical Cancer Research, British Journal of Haematology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact